Key Dates
December 12, 2008 | Cellectis meets the 20 meganucleases annual capacity milestone. |
|---|---|
December 1, 2008 | Cellectis BioResearch, a subsidiary of Cellectis S.A., announces the market launch of a first revolutionary research kit. |
November 20, 2008 | Dr. Dirk Pollet is appointed as Chief Business Officer. |
November 05, 2008 | Publication in NATURE Magazine of an article describing the design of a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis. |
October 23, 2008 | Cellectis and Genomic Vision receive 10 million euros of funding from Oséo-ISI to develop a revolutionary treatment for HIV and herpes. |
September 16, 2008 | The French Muscular Dystrophy Association (AFM) and Cellectis launch a genome surgery program for curing genetic diseases. |
July 3, 2008 | Cellectis and Regeneron sign an agreement over the use of homologous recombination technology. |
June 30, 2008 | Biotechnology company Cellectis S.A. announces the inception of two subsidiaries: Cellectis BioResearch to develop and market research kits and Cellectis Genome Surgery to develop therapeutics. |
April 22, 2008 | Cellectis announces the publication of a paper entitled "Computer design of obligate heterodimer meganucleases allows efficient cutting of custom DNA sequences" in Nucleic Acids Research. |
February 21, 2008 | Cellectis announces positive outcome in IP battle. |
December 6, 2007 | Cellectis announces the publication of a key article in the Journal of Biological Chemistry. |
June 11, 2007 | Cellectis S.A. wins a patent battle in the field of targeted recombination and gene correction. |
June 4, 2007 | The Institut Pasteur and Cellectis announce the grant of a key European patent covering the use of homologous recombination in eukaryotes. |
May 28, 2007 | Cellectis reaches key milestone in collaboration with Bayer Cropscience on uses of Meganuclease technology in plants. |
May 4, 2007 | Cellectis grants GlaxoSmithKline a non-exclusive sub-license for its homologous recombination technology. |
February 6, 2007 | Cellectis S.A. announces the success of its initial public offering on the Alternext market of Euronext Paris. |
October 18, 2006 | Cellectis is distinguished with the Ernst & Young Entrepreneur Award as the "High Prospective Company" of Year 2006. |
October 2, 2006 | Cellectis Appoints Marc Le Bozec As Chief Financial Officer. |
June 30, 2006 | Cellectis and Bayer CropScience enter into a collaboration to use Meganuclease technology in plants. |
April 19, 2006 | Cellectis and Genentech have entered into a worldwide, non-exclusive license agreement. |
March 14, 2006 | Cellectis announces publication of data demonstrating ability of meganucleases to induce efficient in toto recombination in mouse liver. |
February 21, 2006 | Cellectis and Celonic GmbH enter in collaboration and license agreement for mammalian cell lines engineering for bio-production purposes. |
December 20, 2005 | Cellectis sign an Agreement with Shire Pharmaceuticals in the field of gene activated proteins. |
December 13, 2005 | Cellectis signs Worldwide Non-Exclusive License agreement with AstraZeneca covering the use of the Homologous Recombination. |
November 21, 2005 | Cellectis reports the Engineering of large numbers of Novel Highly Specific Homing Endonucleases, in the Journal of Molecular Biology. |
November 3, 2005 | Cellectis distinguished with the Research Company of Year 2005 Award. |
October 18, 2005 | Cellectis is awarded the "Best Pharma Partnering" Trophy 2005 by Pharma Industry Association. |
June 14, 2005 | Cellectis wins patent battle in the field of targeted recombination and gene correction. |
December 16, 2004 | Cellectis is distinguished with the Entrepreneur of the Year 2004 award. |
November 22, 2004 | Cellectis S.A. Grants Lexicon Genetics a Technology Sublicense. |
March 1, 2004 | Cellectis moves to a new facility at Aventis' Biocitech Park, in Romainville, Paris area. |
February 11, 2004 | Cellectis announces a License agreement with Regeneron Pharmaceuticals relating to the use of the Homologous Recombination in Velocigene© Platform. |
June 3, 2003 | Cellectis SA announces publication in Nucleic Acids Research of the generation of a novel hybrid meganuclease. |
May 19, 2003 | Cellectis SA and BASF Plant Science GmbH enter into Technology Agreement. |
March 26, 2003 | Two major patents on homologous recombination issued in the United States. |
March 6, 2003 | Pioneer Hi-Bred to Assess Cellectis Technology for Use in Trait Development. |
September 19, 2002 | Cellectis and Artemis Pharmaceuticals sign a license agreement. |
June 25, 2002 | Cellectis completes its second financing round of 8M €. |
August 30, 2001 | Cellectis and Zentaris sign a license agreement. |
September 20, 2000 | Cellectis is awarded a special prize as the first Biotech Company in nationwide competition. |
January 4, 2000 | Cellectis is incepted as a spin off Institut Pasteur. |
